09:00 - 12:00
主持人 Moderator
- 李佳璇, 芬兰国家商务促进局医疗行业中国区负责人
- Sanorita LI, Head of Heath Industry China, Business Finland
09:00 - 09:20
- 主题报告
- Keynote Speech
- 瑞士:欧洲生命科学热土
- Switzerland: The Life Sciences Hotspot in Europe
- 施万德, 瑞士驻华大使馆贸易与投资处首席投资官兼副主任
- Kuno Gschwend, Deputy Head and Chief Investment Promotion Officer of the Swiss Business Hub China, Embassy of Switzerland in China
09:20 - 09:40
- 项目1
- Project 1
- 先发制癌:RNA表观转录组血检将癌症扼杀于摇篮
- First-Strike Screening with Epitranscriptomics & AI: Stop Colorectal Cancer Before It Exists
- 张理升, 荃慕生物科技首席执行官
- ZHANG Li Sheng, CEO,QuantModE Co., Ltd.
09:40 - 10:00
- 项目2
- Project 2
- 基于AI边缘算法和靶向神经调节技术的降血压穿戴设备
- Based on Edge Al and Targeted Neural Modulation Techniques
- 纪华雷, 加拿大越凡医疗有限公司董事长
- Ray LI, CEO, WAT Medical Enterprise Ltd
10:00 - 10:20
- 项目3
- Project 3
- Radiance Biopharma, a clinical stage biotechnology company developing next generation Antibody Drug Conjugates to treat cancer and other unmet needs
- Radiance Biopharma, A Clinical Stage Biotechnology Company Developing Next Generation Antibody Drug Conjugates to Treat Cancer and Other Unmet Needs
- Robert K. Brook, Radiance Biopharma首席执行官
- Robert K. Brook, CEO,Radiance Biopharma
10:20 - 10:40
- 项目4
- Project 4
- TPD² Approach - Dual-precision Targeted Protein Degradation
- TPD² Approach - Dual-precision Targeted Protein Degradation
- Sungjoo LEE, Orum Therapeutics首席执行官
- Sungjoo LEE, CEO, Orum Therapeutics
10:40 - 11:00
- 项目5
- Project 5
- CytoSpark®微流控高通量筛选系统
- CytoSpark® Microfluidic High-throughput Screening System
- 万玮, Hong Kong DPBio Technology Limited副总裁
- WAN Wei, VP,Hong Kong DPBio Technology Limited
11:00 - 11:20
- 项目6
- Project 6
- 奥克兰岛猪——异种移植及再生医学新平台
- Leading A New Era in Xenotransplantation and Regenerative Medicine
- 黄文静, 新诺生物(香港)有限公司首席执行官
- HUANG Wenjing, CEO,NZeno Biontech (HK) Limited.
11:20 - 11:40
- 项目7
- Project 7
- 计算策略驱动的药物设计方案
- Computational Strategy-driven Drug Design
- 刘天悦, 深度感知生物信息有限公司首席执行官
- LIU Tianyue, CEO, DeepSense Bio Information Co., Ltd.
11:40 - 12:00
- 项目8
- Project 8
- 基于神经体生物标志物与人工智能的便携式体外诊断设备,用于帕金森病早期筛查的验证报告
- Validation of A Portable IVD device for Early Parkinson’s Disease Screening Using Neurosomal Biomarkers and Artificial Intelligence [NEUROSOMIX]
- Robert Jenkins Hamley, Biosomic Technologies, Inc首席执行官
- Robert Jenkins Hamley, CEO of Biosomic Technologies, Inc